This panel covers innate & adaptive immunity, cytokines, chemokines, checkpoints, and cell-death pathways – all captured in a single run.
How our MS-based platform defines a tumor's protein variants in tissue & detects them in blood with high sensitivity.
How next-gen mass spec FFPE proteomics enables retrospective discovery in archived tissue, unlocking new biomarkers & targets.
Learn how protein-level evidence can augment or replace genomic inference at critical drug development decision points.
Using discovery metabolomics to map fetal phenotypes underlying childhood developmental deficiencies.
Turning normal tissue biology from a late-discovered liability into an early part of target evaluation.
See how metabolomics screening translates in vitro injury signatures into real patient outcomes.
Tackling the skepticism that comes with multi-omics initiatives and how to answer, what do we actually do with this data?
Directly measure & quantify degradation, selectivity, and mechanism for PROTACs and molecular glues.
How direct protein-level measurement of the tumor cell surface transforms target discovery.
On the use of comprehensive tumor proteomics to identify cancer targets and biology hiding beyond DNA and RNA.
Expert Q&A on how tumor protein profiling can de-risk oncology programs, delivering novel insights not inferred by genomics.
